Согласованная позиция экспертов о роли гипертриглицеридемии в развитии осложнений сахарного диабета 2 типа
DOI:
https://doi.org/10.34687/2219-8202.JAD.2024.02.0001Ключевые слова:
гипертриглицеридемия, сахарный диабет 2 типа, статины, фенофибрат, омега-3 ПНЖК.Аннотация
Гипертриглицеридемия (ГТГ) широко распространена в группе пациентов с сахарным диабетом 2 типа (СД 2) и требует коррекции, поскольку является фактором риска развития и прогрессирования сердечно-сосудистых заболеваний (ССЗ) и микрососудистых осложнений, в число которых входят диабетическая ретинопатия, хроническая болезнь почек (ХБП) и др. Таким образом, ГТГ у пациентов с СД 2 типа является междисциплинарным вызовом для таких специалистов как: эндокринолог, кардиолог, офтальмолог и нефролог, вовлеченных в ведение пациентов с СД2 типа. В данной статье представлены результаты междисицплинарного совета экспертов, с участием ведущих специалистов Российской ассоциации эндокринологов, Национального общества по изучению атеросклероза, Евразийской ассоциации терапевтов, целью которого было сформировать единое понимание необходимости внедрение целевого уровня триглицеридов >1,7 ммоль/л и создание алгоритма поэтапного достижения цели по параметру триглицериды с учётом коморбидных состояний, часто встречающихся при СД2 типа. В алгоритме ведения пациентов с ГТГ отражены как немедикаментозные методы коррекции, так и этапность подключения фармакотерапии, с выделением клинических этапов применения разных терапевтических методов воздействия на уровень триглицеридов, таких как: статины, фенофибрат и лекарственный препарат Омега-3 ПНЖК.
Скачивания
Библиографические ссылки
Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes
mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of
01.2021. Diabetes mellitus. 2021;24(3):204-221. In Russian. (Дедов И.И., Шестакова М.В., Викулова О.К., Железня-
кова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-
статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204-
https://doi.org/10.14341/DM12759).
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-899. doi: 10.1007/
s00125-015-3525-8.
Li Y, Zhao L, Yu D, Ding G. The prevalence and risk factors of dyslipidemia in different diabetic progression
stages among middle-aged and elderly populations in China. PLoS One. 2018;13(10):e0205709. doi: 10.1371/journal.
pone.0205709.
Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins
and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic
strategies—a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806. doi:
1093/eurheartj/ehab551.
Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, et al. Association Between Triglycerides and
Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From
the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial). Am J Cardiol. 2020;132:36-43.
doi: 10.1016/j.amjcard.2020.07.005.
Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic
Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination
Survey 2007-2014. Diabetes Care. 2019;42(12):2307-2314. doi: 10.2337/dc19-0501.
Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2
diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. doi: 10.2217/clp.10.84.
Ferreira JP, Vasques-Nóvoa F, Ferrão D, Saraiva F, Falcão-Pires I, Neves JS, et al. Fenofibrate and Heart Failure
Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. Diabetes Care. 2022;45(7):1584-1591. doi: 10.2337/
dc21-1977.
Nuyujukian DS, Zhou J, Koska J, Reaven P. 1240-P: Triglyceride Variability and Risk of Adverse Cardiovascular
Outcomes – Results from the ACCORD Trial. Diabetes. 2023;72(1):1240–P. doi: 10.2337/db23-1240-P.
Morieri ML, Shah HS, Sjaarda J, Lenzini PA, Campbell H, Motsinger-Reif AA, et al. PPARA Polymorphism Influences
the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes. 2020;69(4):771-
doi: 10.2337/db19-0973.
Wang Y, Fang Y, Magliano DJ, Charchar FJ, Sobey CG, Drummond GR, Golledge J. Fasting triglycerides are positively
associated with cardiovascular mortality risk in people with diabetes. Cardiovasc Res. 2023;119(3):826-834. doi: 10.1093/
cvr/cvac124.
Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes. 2019;10(5):280-290. doi: 10.4239/
wjd.v10.i5.280.
Balder Y, Vignoli A, Tenori L, Luchinat C, Saccenti E. Exploration of Blood Lipoprotein and Lipid Fraction Profiles
in Healthy Subjects through Integrated Univariate, Multivariate, and Network Analysis Reveals Association of Lipase
Activity and Cholesterol Esterification with Sex and Age. Metabolites. 2021;11:326.
Alexopoulos AS, Qamar A, Hutchins K, Crowley MJ, Batch BC, Guyton JR. Triglycerides: Emerging Targets in Diabetes
Care? Review of Moderate Hypertriglyceridemia in Diabetes. Curr Diab Rep. 2019;19(4):13. doi: 10.1007/s11892-019-1136-3.
Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Wako S, et al. Prognostic Role of Hypertriglyceridemia in Patients
With Stroke of Atherothrombotic Origin. Neurology. 2022;98(16):e1660-e1669. doi: 10.1212/WNL.0000000000200112.
Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, Nordestgaard BG. Elevated LDL Triglycerides
and Atherosclerotic Risk. J Am Coll Cardiol. 2023;81(2):136-152. doi: 10.1016/j.jacc.2022.10.019.
Sezai A, Unosawa S, Taoka M, Osaka S, Obata K, Kanno S, et al. Long-term comparison of ethyl icosapentate vs Omega-
-Acid ethyl in patients with cardiovascular disease and hypertriglyceridemia (DEFAT trial). Circ J. 2019;83(6):1368-
Morieri ML, Rigato M, Fagarazzi C, Avogaro A, Fadini GP. Fibrate use is associated with a lower incidence of
heart failure: A real-world study among people with type 2 diabetes. Atherosclerosis. 2023;379(1):S191. doi: 10.1016/j.
atherosclerosis.2023.06.633.
Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary
analysis of the ACCORDION study. Cardiovasc Diabetol. 2020;19(1):28. doi: 10.1186/s12933-020-01002-x.
Liu X, Zhang J, Zhou W, Liu J, Wang Y. Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic
heart failure patients complicated with diabetes. Cell Mol Biol (Noisy-le-grand). 2023;69(2):110-114. doi: 10.14715/
cmb/2023.69.2.18.
Jo SH, Nam H, Lee J, Park S, Lee J, Kyoung DS. Fenofibrate Use Is Associated With Lower Mortality and Fewer
Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance
Service Cohort. Diabetes Care. 2021;44(8):1868-1876. doi: 10.2337/dc20-1533.
Li J, Shi L, Zhao G, Sun F, NieZ, Ge Z, Gao B, Yang Y. High triglyceride levels increase the risk of diabetic
microvascular complications: a cross-sectional study. Lipids Health Dis. 2023;22(1):109. doi: 10.1186/s12944-023-01873-5.
Yang QH, Zhang Y, Zhang XM, Li XR. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and nonproliferative
diabetic retinopathy in Asian T2DM patients: a systematic review and meta-analysis. Int J Ophthalmol.
;12(2):302-311. doi: 10.18240/ijo.2019.02.19.
Gitay MN, Sohail A, Arzoo Y, Shakir MA. Changes in serum lipids with the onset and progression of Diabetic
Retinopathy in Type-II Diabetes Mellitus. Pak J Med Sci. 2023;39(1):188-191. doi: 10.12669/pjms.39.1.6265.
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on
retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244. doi: 10.1056/NEJMoa1001288.
Shadrichev FE, Grigorieva NN, Shklyarov EB, Kryaneva OYa. The use of fenofibrate in the prevention of the
development of clinically significant changes in the retina in patients with type 2 diabetes mellitus. Ophthalmological
statements. 2010;3(2):17-26. In Russian. (Шадричев Ф.E., Григорьева Н.Н., Шкляров Е.Б., Крянева О.Я Применение
фенофибрата в профилактике развития клинически значимых изменений сетчатки у больных сахарным диа-
бетом 2-го типа. Офтальмологческие ведомости. 2010;3(2):17-26).
Shadrichev FE, Rakhmanov VV, Grigorieva NN, Shklyarov EB. Why might fenofibrate reduce the risk of progression
of diabetic retinopathy in patients with type 2 diabetes? Ophthalmological statements. 2010;3(2):53-59. In Russian.
(Шадричев Ф.Е., Рахманов В.В., Григорьева Н.Н., Шкляров Е.Б. Почему фенофибрат может снижать риск прогре-
сирования диабетической ретинопати у больных сахарным диабетом 2-го типа? Офтальмологческие ведомости.
;3(2):53-59).
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al.; FIELD study investigators. Effect of
fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Lancet. 2007;370(9600):1687-1697. doi: 10.1016/S0140-6736(07)61607-9.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al.; FIELD study investigators. Effects of longterm
fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):
randomised controlled trial. Lancet. 2005;366(9500):1849-1861. doi: 10.1016/S0140-6736(05)67667-2.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the
Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica.
;237(4):185-222. doi: 10.1159/000458539.
Meer E, Bavinger JC, Yu Y, VanderBeek BL. Association of Fenofibrate Use and the Risk of Progression to Vision-
Threatening Diabetic Retinopathy. JAMA Ophthalmol. 2022;140(5):529-532. doi:10.1001/jamaophthalmol.2022.0633.
Kim NH, Choi J, Kim YH, Lee H, Kim SG. Addition of fenofibrate to statins is associated with risk reduction of
diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort
study. Diabetes Metab. 2023;49(3):101428. doi: 10.1016/j.diabet.2023.101428.
Нарушения липидного обмена: клин. рек. МЗ РФ 2022. https://cr.minzdrav.gov.ru/schema/752_1.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control
Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic
Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-
On Study. Diabetes Care. 2016;39(7):1089-1100. doi: 10.2337/dc16-0024.
Stewart S, Lois N. Fenofibrate for Diabetic Retinopathy. Asia Pac J Ophthalmol (Phila). 2018;7(6):422-426. doi:
22608/APO.2018288.
Lin YC, Chen YC, Horng JT, Chen JM. Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic
Patients: A Population-Based Retrospective Cohort Study in Taiwan. Medicina (Kaunas). 2020;56(8):385. doi: 10.3390/
medicina56080385.
Rao BN, Quinn N, Januszewski AS, Peto T, Brazionis L, Aryal N, et al. Retinopathy risk calculators in the prediction of
sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Res Clin Pract. 2022;186:109835.
doi: 10.1016/j.diabres.2022.109835.
Matsuoka-Uchiyama N, Uchida HA, Okamoto S, Onishi Y, Katayama K, Tsuchida-Nishiwaki M, et al. The Association of
Postprandial Triglyceride Variability with Renal Dysfunction and Microalbuminuria in Patients with Type 2 Diabetic
Mellitus: A Retrospective and Observational Study. J Diabetes Res. 2022;2022:3157841. doi: 10.1155/2022/3157841.
Russo GT, De Cosmo S, Viazzi F, Pacilli A, Ceriello A, Genovese S, et al. Plasma Triglycerides and HDL-C Levels
Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative.
Diabetes Care. 2016;39(12):2278-2287. doi: 10.2337/dc16-1246.
Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial
disease. Lancet. 1982;2(8311):1309-1311. doi: 10.1016/s0140-6736(82)91513-6.
Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression
to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes
Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485-493. doi: 10.1053/j.ajkd.2004.11.004.
Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, et al. Benefits of Icosapent Ethyl Across the
Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Circulation. 2021;144(22):1750-1759. doi: 10.1161/CIRCULATIONAHA.121.055560.
Instructions for medical use of the drug Traykor®, film-coated tablets, 145 mg. In Russian. Инструкция по медицин-
скому применению препарата Трайкор®, таблетки, покрытые пленочной оболочкой, 145 мг. РУ: ЛСР-002450/0827.
Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, at al. KDOQI Clinical Practice Guideline
for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-S107. doi: 10.1053/j.ajkd.2020.05.006.
Jacobo-Cejudo MG, Valdés-Ramos R, Guadarrama-López AL, Pardo-Morales RV, Martínez-Carrillo BE, Harbige LS.
Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2
Diabetes Mellitus Patients. Nutrients. 2017;9(6):573. doi: 10.3390/nu9060573.
Kim CH, Han KA, Yu J, Lee SH, Jeon HK, Kim SH, et al. Efficacy and Safety of Adding Omega-3 Fatty
Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual
hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clin Ther. 2018;40(1):83-94. doi:
1016/j.clinthera.2017.11.007.
Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical
Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep. 2020;22(1):5. doi: 10.1007/s11883-020-
-5.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al.; PROMINENT Investigators.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923-1934. doi:
1056/NEJMoa2210645.
Gurevich VS, Koziolova NA, Ezhov MV, Sergienko IV, Alieva AS, Vavilova TV, et al. Unsolved problems of dyslipidemia
and residual cardiovascular risk. The Journal of Atherosclerosis and Dyslipidemias. 2022;1(46):31-39. In Russian.
(Гуревич В.С., Козиолова Н.А., Ежов М. В., Сергиенко И.В., Алиева А.С., Вавилова Т.В. и др. Нерешенные проблемы
дислипидемии и резидуального сердечно-сосудистого риска. Атеросклероз и дислипидемии. 2022;1(46):31-39). doi:
34687/2219-8202.JAD.2022.01.0003.
Ezhov MV, Arutyunov GP. Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with
Hypertriglyceridemia and Metabolic Syndrome. Diseases. 2023;11:140. doi: 10.3390/diseases11040140.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical
Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. Endocr
Pract. 2023;29(5):305-340. doi: 10.1016/j.eprac.2023.02.001.
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. ESC Scientific Document Group.
ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J.
;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2024 Г. П. Арутюнов, Г. Р Галстян, Т. Ю. Демидова, Ф. Х. Дзгоева, М. В. Ежов, В. Ю. Калашников, Г. А. Коновалов, Д. В. Липатов, И. В. Сергиенко, Ф. Е. Шадричев, М. Ш. Шамхалова, М. В. Шестакова
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.